Shareholders could have sold at 1.1 prior to SPP closing and bought back at 1 in the offer. The only risk is that you would be scaled back so I can't see there being a shortfall
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%